{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:35:11Z","timestamp":1791038111187,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":397,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1124\/jpet.123.001681","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T17:05:18Z","timestamp":1691168718000},"page":"252-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations"],"prefix":"10.1016","volume":"387","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-7882","authenticated-orcid":false,"given":"James T.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakshit S.","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Arian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justina C.","family":"Calamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan E.","family":"Rettie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Thummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-1839","authenticated-orcid":false,"given":"Mary F.","family":"Paine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.001681_bib1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00228-021-03266-y","article-title":"Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib","volume":"78","author":"Adiwidjaja","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.123.001681_bib2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1124\/dmd.113.052563","article-title":"A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors","volume":"41","author":"Brantley","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.001681_bib3","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1124\/dmd.31.11.1391","article-title":"Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components","volume":"31","author":"Chatterjee","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.001681_bib4","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0006-2952(97)00100-7","article-title":"Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A","volume":"53","author":"Chiba","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.123.001681_bib5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1124\/pharmrev.120.000106","article-title":"Modeling pharmacokinetic natural product-drug interactions for decision-making: a NaPDI Center recommended approach","volume":"73","author":"Cox","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.123.001681_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00228-011-1108-2","article-title":"Repeated administration of berberine inhibits cytochromes P450 in humans","volume":"68","author":"Guo","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.123.001681_bib7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clpt.2005.01.009","article-title":"In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4\/5 phenotypes","volume":"77","author":"Gurley","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.123.001681_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.clpt.6100222","article-title":"Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo","volume":"83","author":"Gurley","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.123.001681_bib9","first-page":"79","article-title":"Golden seal in early American medical botany","volume":"32","author":"Hobbs","year":"1990","journal-title":"Pharm Hist"},{"key":"10.1124\/jpet.123.001681_bib10","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1124\/jpet.123.001681_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2193-9616-1-9","article-title":"The Simcyp population based simulator: architecture, implementation, and quality assurance","volume":"1","author":"Jamei","year":"2013","journal-title":"In Silico Pharmacol"},{"key":"10.1124\/jpet.123.001681_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425250802691074","article-title":"The Simcyp population-based ADME simulator","volume":"5","author":"Jamei","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/jpet.123.001681_bib13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/dmd.118.081273","article-title":"Selection of priority natural products for evaluation as potential precipitants of natural product-drug interactions: a NaPDI Center recommended approach","volume":"46","author":"Johnson","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.001681_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/138920007780866807","article-title":"Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions","volume":"8","author":"Kalgutkar","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/jpet.123.001681_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.aca.2019.10.029","article-title":"Composite score analysis for unsupervised comparison and network visualization of metabolomics data","volume":"1095","author":"Kellogg","year":"2020","journal-title":"Anal Chim Acta"},{"key":"10.1124\/jpet.123.001681_bib16","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1039\/C8NP00065D","article-title":"Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach","volume":"36","author":"Kellogg","year":"2019","journal-title":"Nat Prod Rep"},{"key":"10.1124\/jpet.123.001681_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4","volume":"36","author":"Kronbach","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.123.001681_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","article-title":"Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes","volume":"32","author":"Lalovic","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.001681_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mol.62.1.162","article-title":"Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism","volume":"62","author":"Lin","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.123.001681_bib20","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1124\/dmd.120.091041","article-title":"Modulation of major human liver microsomal cytochromes P450 by component alkaloids of goldenseal: time-dependent inhibition and allosteric effects","volume":"48","author":"McDonald","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.001681_bib21","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/cpt.2107","article-title":"Assessing transporter-mediated natural product-drug interactions via in vitro-in vivo extrapolation: clinical evaluation with a probe cocktail","volume":"109","author":"Nguyen","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.123.001681_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.001681_bib23","first-page":"14","article-title":"First-pass metabolism of midazolam by the human intestine","volume":"60","author":"Paine","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.123.001681_bib24","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1124\/dmd.117.079962","article-title":"Recommended approaches for pharmacokinetic natural product-drug interaction research: a NaPDI Center commentary","volume":"46","author":"Paine","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.001681_bib25","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1021\/acs.molpharmaceut.7b00406","article-title":"Model-based analysis of biopharmaceutic experiments to improve mechanistic oral absorption modeling: an integrated in vitro in vivo extrapolation perspective using ketoconazole as a model drug","volume":"14","author":"Pathak","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.123.001681_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cger.2021.07.005","article-title":"Over-the-counter remedies in older adults: patterns of use, potential pitfalls, and proposed solutions","volume":"38","author":"Safari","year":"2022","journal-title":"Clin Geriatr Med"},{"key":"10.1124\/jpet.123.001681_bib27","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.001681_bib28","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/0091270003258660","article-title":"Influence of goldenseal root on the pharmacokinetics of indinavir","volume":"43","author":"Sandhu","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.123.001681_bib29","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/cpt.2891","article-title":"Clinical assessment of the drug interaction potential of the psychotropic natural product kratom","volume":"113","author":"Tanna","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.123.001681_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.120.000270","article-title":"Refined prediction of pharmacokinetic kratom-drug interactions: time-dependent inhibition considerations","volume":"376","author":"Tanna","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001681_bib31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.123.001681_bib32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1124\/dmd.119.087007","article-title":"Indinavir increases midazolam N-glucuronidation in humans: identification of an alternate CYP3A inhibitor using an in vitro to in vivo approach","volume":"47","author":"Tian","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.001681_bib33","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1007\/s00216-020-02678-6","article-title":"Identification of adulteration in botanical samples with untargeted metabolomics","volume":"412","author":"Wallace","year":"2020","journal-title":"Anal Bioanal Chem"},{"key":"10.1124\/jpet.123.001681_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/dmd.119.089599","article-title":"Critical impact of drug-drug interactions via intestinal CYP3A in the risk assessment of weak perpetrators using physiologically based pharmacokinetic models","volume":"48","author":"Yamada","year":"2020","journal-title":"Drug Metab Dispos"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524171182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524171182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.001681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:51:37Z","timestamp":1740675097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524171182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0022356524171182"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.001681","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.001681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}